Here is the design of a clinical trial:

Official Title: Microbiota-directed Complementary Food (MDCF) Trial

Included conditions:
- Microbiota
- Complementary Food
- Nutrition

Study Armgroups:
- {'label': 'Intervention arm', 'type': 'EXPERIMENTAL', 'description': 'MDCF2 with four complementary food ingredients (rationale: lead with evidence from Pre-POC clinical trials to optimize lead microbiota-directed complementary food prototypes for their ability to repair microbiota immaturity and positive effects on growth)', 'interventionNames': ['Dietary Supplement: Microbiota Directed Complementary Food (MDCF)']}
- {'label': 'Control arm', 'type': 'ACTIVE_COMPARATOR', 'description': 'Rice-lentil based RUSF (rationale: reference standard of care for MAM; based on knowledge of its effects on the gut microbiota or microbiota immaturity)', 'interventionNames': ['Dietary Supplement: Ready to Use Supplementary Food (RUSF)']}

Interventions:
- {'type': 'DIETARY_SUPPLEMENT', 'name': 'Microbiota Directed Complementary Food (MDCF)', 'description': 'MDCF2 with four complementary food ingredients (rationale: lead with evidence from Pre-POC clinical trials to optimize lead microbiota-directed complementary food prototypes for their ability to repair microbiota immaturity and positive effects on growth)', 'armGroupLabels': ['Intervention arm']}
- {'type': 'DIETARY_SUPPLEMENT', 'name': 'Ready to Use Supplementary Food (RUSF)', 'description': 'Rice-lentil based RUSF (rationale: reference standard of care for MAM; based on knowledge of its effects on the gut microbiota or microbiota immaturity)', 'armGroupLabels': ['Control arm']}

Primary Outcomes:
- {'measure': 'Change in Ponderal growth', 'description': 'Rate of weight gain of the enrolled participants', 'timeFrame': 'At the enrollment (day1), every 15 days during the 3 months of intervention phase and at the end of 1 month of follow up phase by anthropometry'}
- {'measure': 'Change in Linear growth (LAZ),', 'description': 'Rate of skeletal human growth', 'timeFrame': 'At the enrollment (day1), every 15 days during the 3 months of intervention phase and at the end of q month of follow up phase by anthropometry'}
- {'measure': 'Change in Proteomic profile', 'description': 'Information about all proteins that are made in blood, other body fluids, or tissues, at certain times. It will be assayed by Somalogic scan.', 'timeFrame': 'A total of 3 Plasma samples will be collected, just before the start of intervention phase, at the end of first month of intervention phase and just after the completion of 3rd month.'}
- {'measure': 'Change in Morbidity', 'description': 'Refers to having a disease or a symptom of disease. It will be assessed by taking morbidity data.', 'timeFrame': 'Data will be collected every day during the 3 months of intervention phase and once at the end of 1 month of follow up phase.'}
- {'measure': 'Change in microbiota-for-age Z score', 'description': "Bacterial species whose proportional representation define a healthy gut microbiota as it assembles during the first two postnatal years of life.'Microbiota-for-age-Z-score' compares development of a child's fecal microbiota relative to healthy children of similar chronologic age.", 'timeFrame': 'At the enrollment, at the beginning of the intervention phase, weekly during the 1st month of intervention, at the end of 2nd and 3rd months of intervention and at the end of 1 month of follow up phase.'}

Please estimate the sample size based on the assumption: 
80% power, 5% significance level, and 20% attrition rate.
Sample size calculation
        Primary outcome measures will include rate of weight gain, change in weight and length; change in WLZ, change in MUAC, change in LAZ, morbidity, extent of repair of gut microbial community immaturity, and changes in the levels of key plasma biomarkers of host physiological state. We plan to include 124 participants (nÂ =â62/treatment arm) for the primary MAM trial and for the post-SAM MAM trial. Recruitment of 124 participants will give 80% power at 5% significance level based on the change in WLZ scores of children from the recently completed pre-POC trial of different MDCFs. In the pre-POC trial of different MDCFs, the baseline WLZ score of children who received MDCF 2 was ââ2.2 and after 1 month of supplementation was ââ1.7. If we consider the WLZ ââ2 at baseline andâââ1.7 at end line, pooled standard deviation as 0.53, then the sample size would be 49 in each arm at 80% power and 5% level of significance. With 20% attrition, 62 enrolled children will be needed for each arm in each of the two trials.